Fig. 6

CRP model could predict the clinical benefit of Everolimus. A K-M survival analysis assesses the progression-free survival in the Everolimus cohort. B Stacked bar graphs to depict anti-Everolimus monotherapy clinical benefits from CheckMate-025; NCB no clinical benefit, ICB intermediate clinical benefit, CB clinical benefit. C Abnormally differential expression of mTOR-related genes between high- and low-risk CRP score in Everolimus cohort. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns: no significance. D Sankey plot of treatment clinical benefit patterns between CRP score and score. E The oncoplot shows the overview of somatic mutations in the Everolimus-treated patients